Tassos Georgiadis

Tassos Georgiadis

Company: MeiraGTx

Job title: Vice President - Preclinical Development

Bio:

Tassos has been working on retinal gene therapy for 20 years. He has developed AAV vectors for a range of indications that are currently in clinical development (Ph1/2 and Ph3). He is currently VP Preclinical Development at MeiraGTx establishing a multi-platform assessment strategy for drug product candidate screening, with a focus on CNS and retina.

Seminars:

Leveraging the Latest Retinal Organoid Developments 10:10 am

What are the advantages of using iPSC-derived retinal organoids over traditional animal model studies? Understanding the latest developments for their use in gene therapy studies How close are we to seeing FDA guidance documents on retinal organoids?Read more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.